Clinical Trials
23
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (22 trials with phase data)• Click on a phase to view related trials
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
- Conditions
- Idiopathic Short Stature
- Interventions
- Drug: Inpegsomatropin Injection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-07-15
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 300
- Registration Number
- NCT06927310
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Capital Institute of Pediatrics, Beijing (SHOUER), Beijing, Beijing, China
🇨🇳Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Safety, Tolerability, and PK/PD of Telpegfilgrastim Injection in Non-pregnant Females of Childbearing
- First Posted Date
- 2025-04-11
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06924385
- Locations
- 🇨🇳
Peking University Third Hospital, Beijin, Beijing, China
Safety, Tolerability, and PK/PD of Telpegfilgrastim in Premenopausal Non-pregnant Females
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT06893796
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: ACT500 tabletsDrug: Placebo
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT06716905
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
A Follow-up Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B
- Conditions
- Chronic Hepatitis B
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 350
- Registration Number
- NCT06707922
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
Drug Farm and Amoytop Partner on First-in-Class ALPK1 Agonist DF-006 for Hepatitis B and Liver Cancer Treatment
Drug Farm and Xiamen Amoytop Biotech have entered into an option agreement for clinical collaboration on DF-006, a first-in-class ALPK1 agonist targeting hepatitis B and hepatocellular cancer in Greater China.